for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Athenex Inc

ATNX.O

Latest Trade

11.15USD

Change

-0.22(-1.93%)

Volume

281,835

Today's Range

10.98

 - 

11.44

52 Week Range

5.63

 - 

18.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Athenex Announces $225 Million Loan Agreement With Oaktree

* ATHENEX INC - PORTION OF UPFRONT LOAN PROCEEDS BEING USED TO REPAY IN FULL EXISTING DEBT FACILITY

BRIEF-Athenex Says Entered Into $225 Million Senior Secured Loan Agreement

* ATHENEX INC - ON JUNE 19, ENTERED INTO $225 MILLION SENIOR SECURED LOAN AGREEMENT

BRIEF-Athenex Presents Interim Data From Oral Paclitaxel Phase Ii Study In Cutaneous Angiosarcoma At Asco20 Virtual Scientific Program

* ATHENEX PRESENTS INTERIM DATA FROM ORAL PACLITAXEL PHASE II STUDY IN CUTANEOUS ANGIOSARCOMA AT ASCO20 VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Athenex Q1 Loss Per Share $0.24

* ATHENEX, INC. REPORTS FIRST QUARTER ENDED MARCH 31, 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Athenex On Track To Submit NDA For Oral Paclitaxel And Encequidar

* ATHENEX INC - ON TRACK TO SUBMIT NDA FOR ORAL PACLITAXEL AND ENCEQUIDAR Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Athenex Says Arrangement With CEO Johnson Lau, Whereby Lau To Receive Options To Buy Co's Shares In Lieu Of Portion Of Remaining Base Salary For 2020

* ATHENEX - ARRANGEMENT WITH CEO JOHNSON LAU, WHEREBY LAU TO RECEIVE OPTIONS TO BUY CO'S SHARES IN LIEU OF PORTION OF REMAINING BASE SALARY FOR 2020

BRIEF-Athenex Inc's Operational Plans Continue To Remain On Track

* ATHENEX INC - OPERATIONAL PLANS CONTINUE TO REMAIN ON TRACK

BRIEF-Athenex Announces FDA Acceptance For Filing Of U.S. NDA For Tirbanibulin Ointment In Actinic Keratosis

* ATHENEX ANNOUNCES FDA ACCEPTANCE FOR FILING OF U.S. NDA FOR TIRBANIBULIN OINTMENT IN ACTINIC KERATOSIS

BRIEF-Athenex, Inc. Reports Q4 Loss Per Share $0.28

* ATHENEX, INC. REPORTS FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Athenex Meets Enrollment Target For Late Stage Breast Cancer Trial

* ATHENEX MEETS ENROLLMENT TARGET FOR ORAXOL PHASE III CLINICAL TRIAL IN METASTATIC BREAST CANCER

BRIEF-Athenex Says Patient Enrollment For Two Late Stage Studies Of Actinic Keratosis Treatment Completed

* ATHENEX ANNOUNCES EARLY COMPLETION OF PATIENTS ENROLLMENT FOR TWO PHASE III CLINICAL STUDIES OF KX2-391 OINTMENT FOR ACTINIC KERATOSIS Source text for Eikon: Further company coverage:

BRIEF-Athenex Announces Pricing Of Offering Of Common Stock

* ATHENEX, INC. ANNOUNCES PRICING OF OFFERING OF COMMON STOCK

BRIEF-Athenex Announces Proposed Offering Of Common Stock

* SAYS OFFERING 4.30 MILLION COMMON SHARES Source text for Eikon: Further company coverage:

BRIEF-Athenex Announces Encouraging Early Clinical Efficacy And Safety Data Of Oraxol

* ATHENEX ANNOUNCES ENCOURAGING EARLY CLINICAL EFFICACY AND SAFETY DATA OF ORAXOL IN CLINICAL TRIAL FOR THE TREATMENT OF BREAST CANCER

BRIEF-Athenex Files For Offering Of Up To 4.3 Million Shares

* ATHENEX INC FILES FOR OFFERING OF UP TO 4.3 MILLION SHARES - SEC FILING Source text : (http://bit.ly/2Dr3FzB) Further company coverage:

BRIEF-Athenex Announces`Results Of First Cohort Of Phase I Clinical Trial Of Gastric Cancer Treatment

* ATHENEX ANNOUNCES ENCOURAGING RESULTS OF THE FIRST COHORT OF PHASE I CLINICAL TRIAL OF ORAXOL AND CYRAMZA® (RAMUCIRUMAB) COMBINATION TREATMENT IN GASTRIC CANCER Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol

* ATHENEX RECEIVES POSITIVE FEEDBACK FROM FDA ON THE DESIGN OF PHASE III CLINICAL TRIAL FOR ORAXOL

BRIEF-Athenex Announces Chinese FDA Allowance Of Investigational New Drug Application Of Oraxol To Begin Clinical Trials

* ATHENEX ANNOUNCES CHINESE FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION OF ORAXOL TO BEGIN CLINICAL TRIALS

BRIEF-Athenex Receives Promising Innovative Medicine Designation From The UK MHRA For Oraxol

* ATHENEX RECEIVES PROMISING INNOVATIVE MEDICINE DESIGNATION FROM THE UNITED KINGDOM MHRA FOR ORAXOL, AN INNOVATIVE ORAL FORM OF PACLITAXEL Source text for Eikon: Further company coverage:

BRIEF-Athenex Inc ‍Initiates Oral Eribulin Investigational New Drug Development Program For Oncology Indications​

* ATHENEX INC - INITIATION OF AN ORAL ERIBULIN INVESTIGATIONAL NEW DRUG DEVELOPMENT PROGRAM FOR ONCOLOGY INDICATIONS Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up